In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.

The ability to selectively target liposomal anticancer drugs via specific ligands against antigens expressed on malignant cells could improve the therapeutic effectiveness of the liposomal preparations as well as reduce adverse side effects associated with chemotherapy. Long-circulating formulations of liposomes containing lipid derivatives of poly(ethyleneglycol) [sterically stabilized liposomes (SLs)] have been described previously, and new techniques have recently been developed for coupling monoclonal antibodies (Abs) at the poly(ethyleneglycol) terminus of these liposomes. Ab-targeted SLs [immunoliposomes (SILs)] containing entrapped anticancer drugs are predicted to be useful in the treatment of hematological malignancies such as B-cell lymphomas or multiple myeloma, in which the target cells are present in the vasculature. The specific binding, in vitro cytotoxicity, and in vivo antineoplastic activity of doxorubicin (DXR) encapsulated in SILs coupled to monoclonal Ab anti-CD19 (SIL[anti-CD19]) were investigated against malignant B cells expressing CD19 surface antigens. Binding experiments with SIL[anti-CD19] resulted in a 3-fold higher association of the SILs with a human CD19+ B lymphoma cell line (Namalwa) in comparison with nontargeted SLs. Using flow cytometry, fluorescently labeled SIL[anti-CD19] bound to B cells with no recognition of T cells in a mixture of B cells and T cells in culture. Nontargeted SLs demonstrated significantly lower recognition of either B cells or T cells. Targeted DXR-SIL[anti-CD19] displayed a higher cytotoxicity to B cells relative to DXR entrapped in nontargeted SLs. Therapeutic experiments in severe combined immunodeficient mice implanted with Namalwa cells by the i.v. or i.p. routes resulted in significantly increased effectiveness of DXR-SIL[anti-CD19] compared to similar amounts of free DXR, DXR-SL (no Ab), or isotype-matched nonspecific Abs attached to DXR-SL. Single doses (3 mg/kg) of DXR-SIL[anti-CD19] administered i.v. resulted in a significantly improved therapeutic benefit, including some long-term survivors. From our results, we infer that targeted anti-CD19 liposomes containing the anticancer drug DXR may be selectively cytotoxic for B cells and may be useful in the selective elimination of circulating malignant B cells in vivo.

[1]  L. Huang,et al.  Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. , 1995, Biochimica et biophysica acta.

[2]  G. Scherphof,et al.  Processing of different liposome markers after in vitro uptake of immunoglobulin-coated liposomes by rat liver macrophages. , 1987, Biochimica et biophysica acta.

[3]  T. McIntosh,et al.  Structure and phase behavior of lipid suspensions containing phospholipids with covalently attached poly(ethylene glycol). , 1995, Biophysical journal.

[4]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[5]  T. Waldmann,et al.  Immune receptors: targets for therapy of leukemia/lymphoma, autoimmune diseases and for the prevention of allograft rejection. , 1992, Annual review of immunology.

[6]  A. Gabizon,et al.  Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. , 1989, Journal of the National Cancer Institute.

[7]  I. Ahmad,et al.  Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro. , 1992, Cancer research.

[8]  V. Torchilin,et al.  Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. , 1996, Biochimica et biophysica acta.

[9]  P. Greipp.  Advances in the diagnosis and management of myeloma. , 1992, Seminars in hematology.

[10]  T. Tedder,et al.  Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. , 1989, Journal of immunology.

[11]  L. Nadler,et al.  An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. , 1991, Cancer research.

[12]  R. Jain,et al.  Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. , 1994, Cancer research.

[13]  L. Pilarski,et al.  Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma. , 1994, Blood.

[14]  T. Allen,et al.  Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine. , 1992, Cancer research.

[15]  A. Farr,et al.  Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. , 1989, Cancer research.

[16]  J. Uhr,et al.  Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. , 1994, Cancer research.

[17]  A. Scott,et al.  Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. , 1997, Molecular immunology.

[18]  T. Allen,et al.  Long-circulating, polyethylene glycol-grafted immunoliposomes , 1996 .

[19]  L. Pilarski,et al.  Severe deficiency of B lymphocytes in peripheral blood from multiple myeloma patients. , 1984, The Journal of clinical investigation.

[20]  G. Storm,et al.  Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. , 1993, Biochimica et biophysica acta.

[21]  R. G. Anderson,et al.  Assembly of clathrin-coated pits onto purified plasma membranes. , 1987, Science.

[22]  L. Pilarski,et al.  Intrinsic expression of the multidrug transporter, P-glycoprotein 170, in multiple myeloma: implications for treatment. , 1995, Leukemia & lymphoma.

[23]  V. Ghetie,et al.  Immunotoxins in the therapy of cancer: from bench to clinic. , 1994, Pharmacology & therapeutics.

[24]  V. Torchilin,et al.  Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo , 1991, FEBS letters.

[25]  J. Ritz,et al.  Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. , 1992, Blood.

[26]  S. Zalipsky.  Synthesis of an end-group functionalized polyethylene glycol-lipid conjugate for preparation of polymer-grafted liposomes. , 1993, Bioconjugate chemistry.

[27]  K. Miyajima,et al.  Physical-chemistry characteristics and biodistribution of poly(ethylene glycol)-coated liposomes using poly(oxyethylene) cholesteryl ether. , 1995, Chemical & pharmaceutical bulletin.

[28]  J. Mason,et al.  Geometric packing constraints in egg phosphatidylcholine vesicles. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[29]  L. Huang,et al.  Monoclonal antibody targeting of liposomes to mouse lung in vivo. , 1989, Cancer research.

[30]  S. Akiyama,et al.  Non-P-glycoprotein-mediated multidrug-resistant human KB cells selected in medium containing adriamycin, cepharanthine, and mezerein , 1994, Somatic cell and molecular genetics.

[31]  L. Mayer,et al.  Vesicles of variable sizes produced by a rapid extrusion procedure. , 1986, Biochimica et biophysica acta.

[32]  I. Ahmad,et al.  Immunoliposome-mediated targeting of anti-cancer drugs in vivo. , 1995, Biochemical Society transactions.

[33]  T. Allen,et al.  A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. , 1995, Biochimica et biophysica acta.

[34]  P. Tyle,et al.  Monoclonal antibodies, immunoconjugates, and liposomes as targeted therapeutic systems. , 1990, Targeted diagnosis and therapy.

[35]  Y. Kurosawa,et al.  Preparation and characterization of a chimeric CD 19 monoclonal antibody , 1991, Immunology and cell biology.

[36]  F. Szoka,et al.  Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. , 1979, Biochimica et biophysica acta.

[37]  J. Ziegler,et al.  Bone marrow involvement in Burkitt's lymphoma and its relationship to acute B-cell leukemia. , 1980, Leukemia research.

[38]  M. Papisov,et al.  Why do Polyethylene Glycol-Coated Liposomes Circulate So Long?: Molecular Mechanism of Liposome Steric Protection with Polyethylene Glycol: Role of Polymer Chain Flexibility , 1994 .

[39]  I. Slaper-Cortenbach,et al.  Preclinical studies with radiolabeled monoclonal antibodies for treatment of patients with b‐cell malignancies , 1994, Cancer.

[40]  K. Foon,et al.  Immunologic classification of leukemia and lymphoma. , 1986, Blood.

[41]  J. Weinstein,et al.  Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier". , 1992, Cancer research.

[42]  G Blume,et al.  Molecular mechanism of the lipid vesicle longevity in vivo. , 1993, Biochimica et biophysica acta.

[43]  G. R. Bartlett.  Phosphorus assay in column chromatography. , 1959, The Journal of biological chemistry.

[44]  Theresa M. Allen,et al.  Pharmacokinetics of long-circulating liposomes , 1995 .

[45]  L. Pilarski,et al.  Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. , 1992, Hematology/oncology clinics of North America.

[46]  T M Allen,et al.  Large unilamellar liposomes with low uptake into the reticuloendothelial system , 1987, FEBS letters.

[47]  T. Allen,et al.  Pharmacokinetics of stealth versus conventional liposomes: effect of dose. , 1991, Biochimica et biophysica acta.

[48]  Y. Barenholz,et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.

[49]  B. Wolff,et al.  The use of monoclonal anti-Thy1 IgG1 for the targeting of liposomes to AKR-A cells in vitro and in vivo. , 1984, Biochimica et biophysica acta.

[50]  S. Larson,et al.  Recent achievements in the development of radiolabeled monoclonal antibodies for diagnosis, therapy and biologic characterization of human tumors. , 1993, Acta oncologica.

[51]  P. Low,et al.  Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. , 1995, Biochimica et biophysica acta.

[52]  T. Schumacher,et al.  Regulatory role of CD19 molecules in B-cell activation and differentiation. , 1989, Cellular immunology.

[53]  C. Cass,et al.  Multidrug resistance of a continuously differentiating monoclonal B lineage in the blood and bone marrow of patients with multiple myeloma. , 1992, Current topics in microbiology and immunology.

[54]  J. Kemshead,et al.  The potential of targeted radiotherapy in the treatment of central nervous system leukaemia. , 1994, Leukemia & lymphoma.

[55]  P. Trail,et al.  Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. , 1993, Science.

[56]  T. D. de Witte,et al.  Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins. , 1994, Cancer research.

[57]  S. Hakomori,et al.  Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. , 1985, Cancer research.

[58]  Y. Barenholz,et al.  Ammonium Sulfate Gradients for Efficient and Stable Remote Loading of Amphipathic Weak Bases into Liposomes and Ligandoliposomes. , 1994 .

[59]  I. Ahmad,et al.  Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. , 1993, Cancer research.

[60]  T. Allen,et al.  Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. , 1993, Biochimica et biophysica acta.